Last Updated:
4:10 pm
Tuesday, July 8, 2025
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
asx-imu
Market Cap
AU$112.01M
Volume
548634
Open
0.41
AU$
High
0.44
AU$
Low
0.40
AU$
Shares On Issue
218M
52 Week Low
0.34
AU$
52 Week High
2.754
AU$
Website
www.imugene.com
Consensus
N/A
Last Report Date
N/A
Next Report Date
N/A
Next Dividend date
N/A
Short Sell
N/A
Short Sell Change (1mth)
N/A
Free ASX Market Outlook & Top Stock Picks for 2025
Instantly access our exclusive report and see which stocks our analysts are backing for growth this year.
Download Free Report
Related
Our friendly team is here to help.
If you have any questions or feedback about our service, please feel free to contact us.
© Australian Stock Report Pty Ltd. All rights reserved